Wellinks Names New CEO Stacie Bratcher

July 13, 2023
A woman named Stacie smiling at the camera - Wellinks ImagesA woman named Stacie smiling at the camera - Wellinks Images
Table of Contents

NEW HAVEN, Conn., July 13, 2023 -- Wellinks, the leading digital healthcare company offering virtual cardiopulmonary disease management for health plans and value-based care providers, today announced Stacie Bratcher as its new Chief Executive Officer.


Bratcher brings more than 20 years of experience leading companies delivering innovative cardiopulmonary care, most recently serving as CEO of Jet Health, a home health and hospice company, and, prior to that, as CEO of Alana Healthcare, a value-based chronic condition management company focused on chronic obstructive pulmonary disease (COPD) and congestive heart failure (CHF). A licensed physical therapist, her background in rehabilitation services includes multiple settings from outpatient to skilled nursing in both public and privately held companies. She also serves as the Board Chair at GripAble, a London-based digital health company moving into the U.S. market.

More than one-in-five patients with COPD also have CHF, and complications of CHF can cause COPD if left untreated. The prevalence of both conditions is increasing, and it is estimated that by 2030, 23.6 million Americans will have COPD and 8.2 million will have CHF. Building on Bratcher’s experience successfully leading and scaling companies addressing challenges for both diseases, Wellinks is strengthening its capabilities for holistically addressing the needs of patients with CHF in addition to COPD.

“Stacie is the perfect candidate to guide Wellinks as we bring on new opportunities,” said Kevin Rakin, Chair of Wellinks’ Board. “Her deep expertise in the industry will accelerate Wellinks’ ability to unite key players across the continuum of care to deliver a better experience for medically complex patients.”

“The intersections of value-based arrangements and innovative approaches to care provide unique opportunities to better manage chronic diseases,” said Bratcher. “Wellinks has fundamentally changed the way we think about delivering virtual cardiopulmonary care – I’m excited to lead the company’s expansion and help our partners bring a new standard of care to their members.”

This appointment comes at a time of great momentum for Wellinks. The company recently announced an agreement with Highmark Blue Cross Blue Shield Delaware to deliver integrated COPD care for members in the state.

About Wellinks
Wellinks is on a mission to help those with chronic obstructive pulmonary disease (COPD) live fully and breathe freely. COPD is the third leading cause of death by chronic disease in the U.S. and the fifth most costly chronic disease. With its personalized, virtual-first COPD management system, Wellinks breaks down barriers for patients, providing the evidence-based care they need and deserve outside the four walls of the clinic. Wellinks supports patients through virtual care, including pulmonary rehabilitation, health coaching, and monitoring aided by connected devices and an easy-to-use smartphone app. Based in New Haven, Connecticut, Wellinks is led by a team of experienced healthcare leaders and backed by top investment firms including Morningside, HighCape Capital, Connecticut Innovations, and Benslie. For more information, visit www.wellinks.com and follow on Twitter (@WellinksHealth) and LinkedIn.

Press Contact:
[email protected]

NEW HAVEN, Conn., July 13, 2023 -- Wellinks, the leading digital healthcare company offering virtual cardiopulmonary disease management for health plans and value-based care providers, today announced Stacie Bratcher as its new Chief Executive Officer.


Bratcher brings more than 20 years of experience leading companies delivering innovative cardiopulmonary care, most recently serving as CEO of Jet Health, a home health and hospice company, and, prior to that, as CEO of Alana Healthcare, a value-based chronic condition management company focused on chronic obstructive pulmonary disease (COPD) and congestive heart failure (CHF). A licensed physical therapist, her background in rehabilitation services includes multiple settings from outpatient to skilled nursing in both public and privately held companies. She also serves as the Board Chair at GripAble, a London-based digital health company moving into the U.S. market.

More than one-in-five patients with COPD also have CHF, and complications of CHF can cause COPD if left untreated. The prevalence of both conditions is increasing, and it is estimated that by 2030, 23.6 million Americans will have COPD and 8.2 million will have CHF. Building on Bratcher’s experience successfully leading and scaling companies addressing challenges for both diseases, Wellinks is strengthening its capabilities for holistically addressing the needs of patients with CHF in addition to COPD.

“Stacie is the perfect candidate to guide Wellinks as we bring on new opportunities,” said Kevin Rakin, Chair of Wellinks’ Board. “Her deep expertise in the industry will accelerate Wellinks’ ability to unite key players across the continuum of care to deliver a better experience for medically complex patients.”

“The intersections of value-based arrangements and innovative approaches to care provide unique opportunities to better manage chronic diseases,” said Bratcher. “Wellinks has fundamentally changed the way we think about delivering virtual cardiopulmonary care – I’m excited to lead the company’s expansion and help our partners bring a new standard of care to their members.”

This appointment comes at a time of great momentum for Wellinks. The company recently announced an agreement with Highmark Blue Cross Blue Shield Delaware to deliver integrated COPD care for members in the state.

About Wellinks
Wellinks is on a mission to help those with chronic obstructive pulmonary disease (COPD) live fully and breathe freely. COPD is the third leading cause of death by chronic disease in the U.S. and the fifth most costly chronic disease. With its personalized, virtual-first COPD management system, Wellinks breaks down barriers for patients, providing the evidence-based care they need and deserve outside the four walls of the clinic. Wellinks supports patients through virtual care, including pulmonary rehabilitation, health coaching, and monitoring aided by connected devices and an easy-to-use smartphone app. Based in New Haven, Connecticut, Wellinks is led by a team of experienced healthcare leaders and backed by top investment firms including Morningside, HighCape Capital, Connecticut Innovations, and Benslie. For more information, visit www.wellinks.com and follow on Twitter (@WellinksHealth) and LinkedIn.

Press Contact:
[email protected]

Driving Better Outcomes
COPD foundation logo and Wellinks logo - Wellinks Images

Wellinks is excited to announce the final results of ASPIRE – a clinical trial conducted with the COPD Foundation to assess the impact of Wellinks on quality of life, engagement and satisfaction among COPDF members living with COPD.

Circle with 3 images- laptop, smartphone and call screenshot - Wellinks Images
Each participant received personalized health coaching, virtual pulmonary rehabilitation, and monitoring through connected devices and a patient-facing app.

The study enrolled 141 members in the trial, with 119 completing the 24-week study. These results demonstrate sustained engagement, satisfaction, and clinical response with Wellinks.

Interested in learning more about Wellinks?

Request a Demo Today

Wellinks Engagement at 24 Weeks
(n = 141)

61%
Finger pressing the "Join" button - Wellinks Images
Enrollment Rate

Proportion successfully enrolled out of all who were interested and eligible

84%
Two hands shaking - Wellinks Images
Retention Rate

Proportion who remained enrolled in the study at 24 weeks

These results were demonstrated in a population with...

Web stats - Wellinks Images

High Member Satisfaction at 24 Weeks

  • Over 81% said Wellinks helped them better manage their COPD
  • Over 92% found Wellinks to be valuable
  • Over 83% said Wellinks helped them learn more about their COPD
+64
Net Promoter Score*
* Net Promoter Score (NPS) is a customer loyalty and satisfaction measurement taken from asking customers how likely they are to recommend your product. NPS scores range from -100 to +100. This NPS is based on responses from those who continued contact with coaches, representative of the Wellinks clinical model.

Improved Clinical Outcomes at 24 Weeks

Healthcare icon - Wellinks Images
Wellinks demonstrated sustained improvements in COPD self-efficacy as measured by the COPD Self-efficacy Scale (CSES) at 24 weeks.
Respiratory icon - Wellinks Images
Self-efficacy is a measure of how confident an individual is in managing their COPD and addressing shortness of breath.
Magnifying glass icon - Wellinks Images

One-third of participants demonstrated improvements in Modified Medical Research Council dyspnea score. mMRC is a measure of breathlessness that is associated with risk of future exacerbations.

Sign up to stay updated on ASPIRE and Wellinks.

Thank you! Stay tuned for more Wellinks news soon.

Oops! Something went wrong while submitting the form.
*By providing your email address, you agree to opt into receiving our Wellinks marketing emails.
You can unsubscribe at any time. Your information will be held confidential.